III.L 0MSFT 0.31GO.U.TO 0.3CIU.PR.A.TO 0DAL -0.02CDZ.TO 0.42NET -0.42KLAC 1.81
Amgen Inc. (AMGN)

NASDAQ:AMGN

Amgen Inc. (AMGN)

373.76
-0.39 (0.10%)
as of Jul 2, 2026, 10:54:55 pm Market Open.
106 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 5, 2026, 12:00 am

This summary was created by AI, based on 17 opinions in the last 12 months.

Amgen Inc. (AMGN) is highly regarded among experts for its stable management and well-executed innovative pipeline, featuring 15 products that have demonstrated double-digit revenue growth. Multiple analysts highlight the company's promising GLP-1 weight-loss drug currently in phase 3 testing, pointing to its potential as a game-changer in the market. Despite some concerns about slower growth compared to peers, many see AMGN as a safer investment within the biotech sector, especially given its reasonable forward P/E ratio below 20x and attractive dividend yield, which is around 3.23% to 3.46%. The stock appears to be breaking out to new highs and has recently been upgraded, reinforcing the belief in its upward trajectory as the industry evolves. Overall, AMGN is considered a solid holding for investors looking for exposure to large-cap biotech, particularly with strong earnings potential and an optimistic outlook steering toward 2027.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
GILD
TOP PICK

Amgen Inc.(AMGN)

Aug 13, 2004
A very rapidly growing company. Earnings per share growth is in excess of 20% yearly. PE ratio barely more than that.
Photo of Samuel D. IsalySamuel D. Isaly
Owned
Unlock Rating
$54.36

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Jul 16, 2004
Under a cloud. Driven down because of generic drugs and imports from Canada. Medicare will be onerous. Powerful balance sheet.
Photo of Alan BlakeAlan Blake
Owned
Unlock Rating
$55.73

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

May 14, 2004
Health care should outperform in a rising interest rate environment. A premier company. Likes the pipeline that it has. Out-of-favor right now.
Photo of Nicholas SargenNicholas Sargen
Owned
Unlock Rating
$56.65

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

May 11, 2004
(A top pick in Feb/04. Down a bit.) This sector has great prospects on a going forward basis but will be volatile on a short-term basis. A leader in their field. Good growth prospects.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$57.14

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Apr 02, 2004
Photo of Nicholas SargenNicholas SargenUnlock Rating
$59.51

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Mar 09, 2004
A leading biotech company. Trading at 22 X next year's earnings. Pretty cheap for this quality of a company.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$62.76

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Dec 29, 2003
A very mature biotech company. Expects about 10/15% revenue growth and about 20/25% earnings growth. Trading at a low multiple.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$61.87

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Nov 03, 2003
(A top pick July 15/03. Down 13.7%.) Sold the stock in the summer.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$61.15

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Nov 03, 2003
Has made some good acquisitions in the last couple of years, which has propped up their product line. 25 X next year's earnings.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$61.19

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Oct 22, 2003
They don't have the problem of drugs going off patent. The stock can go much higher. Dropping currently because the sector is pulling it down.
Photo of Paul O'NeilPaul O'Neil
No
Unlock Rating
$60.30

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Jul 22, 2003
Was a top pick on Jun 4/03. Up 7%.) The leader in bio techs. Has grown its earnings every year since 1994.
Photo of David BurrowsDavid BurrowsUnlock Rating
$68.93

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Jul 15, 2003
A lot of drug products in the pipeline. Cash flow is growing.
Photo of David BurrowsDavid BurrowsUnlock Rating
$71.54

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Jul 02, 2003
Has made money every year going back to 1994. Good cash flow.
Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
$67.21

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Jun 04, 2003
A safe way of investing in biotechs. Has held up through poor periods. Has a broad pipeline of products.
Photo of David BurrowsDavid BurrowsUnlock Rating
$64.49

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

May 26, 2003
Has better earnings and price momentum than Biogen going forward. Likes both Biogen and Amgen, but Amgen is their first choice.
Photo of Peter Arender, CFAPeter Arender, CFAUnlock Rating
$61.88

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
Showing 136 to 150 of 165 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NFLX 0$77.65
GOOG -0.5$355.68
CAT 1.47$965
NFLX 0$77.65
AAPL -0.2$308.43

Today's Top Picks

III.L 0$2999
MSFT 0.31$390.8
GO.U.TO 0.3$9.55
CIU.PR.A… 0$
DAL -0.02$92.73

Popular Articles

Latest Sell Signals

CAT 1.47$965
ASML 5.87$1775.1899
TRI.TO -1.74$124.88
EIF.TO 2.09$132.94
MU 0.84$976.4

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Josh Brown, CEO, Ritholtz Wealth Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Michael Hakes - CFA, MBA

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like